Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Platinum-Resistant Recurrent Ovarian Cancer
NCT03587129Phase 2Terminated
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in ovarian cancer, sponsored by The First Affiliated Hospital of Harbin Medical University. Started Jul 2018; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03587129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587129.